Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Submitted by
admin
on April 27, 2017 - 9:14am
Source:
Marketwatch
News Tags:
Neurocrine
drug pricing
Ingrezza
tardive dyskinesia
Headline:
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Do Not Allow Advertisers to Use My Personal information
